Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 23.08 USD 0.44% Market Closed
Market Cap: 1.1B USD

Urogen Pharma Ltd
Other Long-Term Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Urogen Pharma Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Urogen Pharma Ltd
NASDAQ:URGN
Other Long-Term Assets
$6.9m
CAGR 3-Years
37%
CAGR 5-Years
87%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Other Long-Term Assets
$99.2m
CAGR 3-Years
-14%
CAGR 5-Years
104%
CAGR 10-Years
99%
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Other Long-Term Assets
$359k
CAGR 3-Years
-5%
CAGR 5-Years
27%
CAGR 10-Years
28%
Entera Bio Ltd
NASDAQ:ENTX
Other Long-Term Assets
$92k
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Other Long-Term Assets
$2.4m
CAGR 3-Years
23%
CAGR 5-Years
28%
CAGR 10-Years
12%
M
Matricelf Ltd
TASE:MTLF
Other Long-Term Assets
₪96k
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Urogen Pharma Ltd
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

URGN Intrinsic Value
29.67 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Urogen Pharma Ltd's Other Long-Term Assets?
Other Long-Term Assets
6.9m USD

Based on the financial report for Sep 30, 2025, Urogen Pharma Ltd's Other Long-Term Assets amounts to 6.9m USD.

What is Urogen Pharma Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
87%

Over the last year, the Other Long-Term Assets growth was 1 173%. The average annual Other Long-Term Assets growth rates for Urogen Pharma Ltd have been 37% over the past three years , 87% over the past five years .

Back to Top